Here are the 10-K annual reports from Intensity Therapeutics, Inc. (INTS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow INTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INTS filings page.
Intensity Therapeutics files its annual report describing a late-stage oncology pipeline built around lead intratumoral candidate INT230-6, which combines cisplatin, vinblastine and an amphiphilic enhancer to kill solid tumors locally while stimulating systemic immune responses.
The report highlights completed Phase 1/2 and Phase 2 data showing substantial tumor necrosis, abscopal effects and a generally favorable safety profile, with over 95% of active agents retained in tumors. Ongoing programs include the Phase 3 INVINCIBLE-3 trial in metastatic soft tissue sarcoma and the Phase 2 INVINCIBLE-4 trial in presurgical triple‑negative breast cancer, both designed around dosing based on tumor burden.
Due to funding constraints, new site activations and enrollment in INVINCIBLE-3 and enrollment in INVINCIBLE-4 were temporarily paused, although already-enrolled patients continue treatment and Swiss regulators have approved a revised dosing regimen for INVINCIBLE-4. As of March 26, 2026, the company had 2,540,518 common shares outstanding after a 1-for-25 reverse stock split.